Matricelf Reports Statistically Significant Motor Function Improvement in Preclinical Efficacy Study of Chronic Spinal Cord Injury

Ness Ziona, Israel--(. - November 5, 2026) - Matricelf Ltd. TASE:MTLF, a biotechnology company developing personalized engineered neural tissue for spinal cord injury, today announced positive results from its comprehensive preclinical efficacy study, demonstrating statistically signif…